Voss MH, et al. - Researchers tested dalantercept (a novel antiangiogenic targeting activin receptor-like kinase 1) plus axitinib in a phase 2, randomized, double-blind, placebo-controlled study in patients with clear cell renal cell carcinoma (RCC) previously treated with one prior angiogenesis inhibitor. Using randomization stratified by the type of prior therapy, participants were randomly assigned 1:1 to axitinib plus dalantercept vs axitinib plus placebo. Progression-free survival (PFS) was considered the primary endpoint. PFS in patients with ≥2 prior lines of anticancer therapy, overall survival, and the objective response rate were the secondary endpoints. Dalantercept plus axitinib was well tolerated by the patients, however, in previously treated patients with advanced RCC this treatment strategy did not improve treatment-related outcomes.